Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape

from IMPACT Medicom · host IMPACT Medicom

In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL. Our Guest:Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Research Institute in Oncology and Hematology, based in Winnipeg, Manitoba.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.comThis episode was funded by Eli Lilly, Canada.

Episode metadata supplied by the publisher feed · Published Sep 4, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape

0:00 17:37

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of IMPACT Medicom?

This episode is 17 minutes long.

When was this IMPACT Medicom episode published?

This episode was published on September 4, 2024.

Can I download this IMPACT Medicom episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!